TNK

(redirected from Tenecteplase)
Also found in: Medical, Wikipedia.
AcronymDefinition
TNKTank
TNKTomorrow Never Knows (Beatles song)
TNKTenecteplase
TNKTanak
TNKTyumenskaya Neftyanaya Kompaniya (Tyumen Oil Company, Russia)
TnKTenshi Na Konamaiki (anime)
TNKTrue North Knives (Montreal, QC, Canada)
TNKThe Neighbor Kids (band)
TNKTorah Neviim Ktuvim (Hebrew: old testiment)
References in periodicals archive ?
She had no contraindications to thrombolytic therapy and therefore paramedics administered Tenecteplase.
0 mg/mL; urokinase, 100 U/mL; streptokinase, 125 000 IU/mL; tenecteplase, 5 mg/mL; reteplase, 1U/mL.
The conclusion was, therefore, that tenecteplase is non-inferior to alteplase.
Minutes later, paramedic Gail Stewart arrived on the scene and Thomas became the 100th patient to be given Tenecteplase by a paramedic.
Tenecteplase is a recently developed reengineered isomer of tissue plasminogen activator that possesses many properties of the ideal cardiac arrest thrombolytic agent.
Alteplase (Activase), reteplase (Retavase), and tenecteplase (TNKase), produced with recombinant DNA technology are not teratogenic in experimental animals and are all rated C.
In STREAM, the bolus thrombolytic agent tenecteplase (Metalyse(R)) will be administered prehospitally to patients presenting early (within 3 hours) after symptom onset.
Following administration of atropine in accord with standard CPR protocol, patients were randomized to fibrinolytic therapy with tenecteplase or placebo given in the field by EMS personnel or physicians as CPR continued.
Birmingham and Black Country primary care trusts have now approved funding for West Midlands Ambulance Service to use the heart drug tenecteplase, even though neighbouring services have been using it for years.
The only drawback with the scheme is that paramedics will have to use a more expensive heart drug called Tenecteplase which costs pounds 570 a dose.
TENECTEPLASE TREATMENT OF FULMINANT PULMONARY EMBOLISM IN CARDIAC ARREST RESULTS IN SURVIVAL AFTER REFRACTORY CPR.
INTEGRITI (INTEGRIlin and Tenecteplase in Acute Myocardial Infarction), announced last year during the American Heart Association's Annual Scientific Sessions, is a collaboration between COR Therapeutics, Inc.